Health Canada's New NHP Quality Guide: What Changes Since 2015

For eleven years, the quality of every natural health product sold in Canada has been measured against a single guidance document that has not changed since 2015. That is about to end. On 20 July 2026, Health Canada released a draft revised Quality of Natural Health Products Guide, version 4.0, and opened it for public comment. The consultation closes on 20 September 2026, and a final version is expected later this year with a transition period to follow.

This is a different document from the good manufacturing practices guide, GUI-0158, that most of the industry has been talking about all year. The GMP guide, which governs how you manufacture, tells you how to run your site. The Quality Guide tells you what your product must actually be shown to be. If you build finished product specifications against the wrong document, you will still have a gap. This article explains what the draft version 4.0 changes, why it matters, and what natural health product licence holders should do before the comment window closes.

Executive summary

The draft Quality of Natural Health Products Guide, version 4.0, is the first revision since version 3.1 of May 2015. It sets out how a licence holder must demonstrate the identity, quantity, potency, purity and stability of a finished natural health product, and it makes the purity and elemental impurity expectations far more explicit than the 2015 text. It confirms that, under paragraph 44(2)(a) of the Natural Health Products Regulations, detailed purity information must appear in your finished product specifications. It aligns elemental impurity limits with ICH guideline Q3D and permitted daily exposures, and it adds direct guidance on the in-use period for multiple-dose products. Any specification written against the 2015 guide should be reviewed against the draft now, not after the final version lands.

What is the Quality of Natural Health Products Guide?

The Quality of Natural Health Products Guide is Health Canada's statement of how a licence holder demonstrates that a finished natural health product has the identity, quantity, potency, purity and stability it claims. It is the reference behind the quality section of a product licence application and the finished product specifications that support it. The draft version 4.0 was published for consultation on 20 July 2026 and replaces version 3.1, dated May 2015.

Why it matters: this guide is where Health Canada spells out the evidence it expects to see for product quality. A specification that satisfied the 2015 guide may no longer meet the current interpretation of the regulations. What to do: read the draft against your existing specifications, identify where the expectations have tightened, and decide whether to submit a comment before 20 September 2026 or simply begin closing the gaps.

What changed from version 3.1 to draft version 4.0

Health Canada states that the revised guide gives additional guidance to reflect current science while offering flexibility where it makes sense, and that it is clearer and easier to use. In practice, the biggest movements are in purity, elemental impurities and stability, where the draft imports concepts that pharmaceutical manufacturers already know from ICH guidelines. The table below maps the main quality areas and what to look for in the draft.

The single most useful mental model is this: version 4.0 moves the natural health product quality file closer to pharmaceutical expectations, especially on impurities. If your team already works to ICH standards for a drug line, much of the draft will feel familiar. If your only reference has been the 2015 guide, the elemental impurity and in-use sections are where you are most likely to find a gap.

Purity and elemental impurities

What it is: purity is the demonstration that your product is free from contaminants and impurities beyond justified limits. The draft is direct. As required under paragraph 44(2)(a) of the Natural Health Products Regulations, you must include detailed information about the purity of your product in its finished product specifications. Why it matters: purity is not a single test, it is a set of controls covering physical, chemical and microbial contaminants, adulterants, and related and process-related impurities. What to do: confirm your specifications address each category with a justified acceptance criterion, not a generic pass statement.

On elemental impurities, the draft is explicit that a product must not contain elemental impurities that exceed the permitted daily exposures, or PDEs. It points to ICH guideline Q3D on elemental impurities for the method to calculate concentration limits and to determine a PDE, and it directs manufacturers who test at the raw material stage to calculate the total daily exposure in the finished product, referencing USP General Chapter <2232> on elemental contaminants in dietary supplements. The draft also notes that limits for topical products differ from oral products, and it flags elements such as arsenic, cadmium, lead and mercury for special attention.

Stability and the in-use period

What it is: stability data is the evidence that a product keeps its identity, potency and purity across its shelf life. Why it matters: the draft ties your stability specifications to the expiry date you print, and it adds guidance many licence holders have never formally addressed. What to do: confirm your stability programme supports every claim on the label, including any in-use statement, and read it alongside the stability programme expectations under GUI-0158, which govern how those studies are run and retained at your site.

The in-use period is the new emphasis worth flagging. The draft states that if your product carries an in-use period on its label, that statement must be truthful and supported by appropriate stability study results. It expects the study to mimic real consumer use, for example testing at or near the expiry date after the product has been opened, sampled and closed multiple times through the shelf life. It calls out sterile and non-sterile multiple-dose products in particular, such as ophthalmic products and products used on open wounds or burns. If you make an in-use claim without opened-container data behind it, that is a gap you can close now.

Finished product specifications and paragraph 44(2)(a)

The finished product specification, or FPS, is the document that ties the whole quality file together. It lists the tests, methods and acceptance criteria that define an acceptable batch. Paragraph 44(2)(a) of the regulations is the legal anchor the draft leans on for purity, and the wider FPS carries the identity, quantity, potency and stability criteria as well. A recent change means that finished product specifications are no longer submitted with Class II and Class III applications, but the duty to hold and maintain a compliant FPS has not gone away. Health Canada can request it at any time, and it must reflect the current quality expectations.

Where the FPS meets the supply chain is often where the gaps hide. Purity and elemental impurity control begins with raw materials, so raw material specifications should include the relevant purity tests. Getting this right depends on knowing whether your input is a raw material or a finished natural health product, because that classification decides which specifications and controls apply. Build the specification from the raw material forward, and the finished product criteria become much easier to defend.

Quality Guide or GMP Guide? Do not confuse the two

This is the point most of the market is getting wrong. Health Canada maintains two separate quality documents for natural health products, and they answer two different questions. The GMP guide, GUI-0158, tells you how to run a compliant site. The Quality Guide tells you what your product must be shown to be. You need both, and a strong site quality system does not compensate for a weak product specification.

If you have been focused on your site licence and GMP obligations, including the end of finished product self-report numbers and site licence compliance, the Quality Guide is the companion piece you cannot skip. The two documents work together, and an inspector or reviewer will expect your product evidence and your site systems to line up.

Compliance checklist: readiness for the new Quality Guide

• Read the draft version 4.0 against every current finished product specification and note where expectations have tightened.
• Confirm your specifications include detailed purity information as required under paragraph 44(2)(a).
• Check elemental impurity controls against ICH Q3D permitted daily exposures, using your actual daily dose and the lowest body weight in your recommended population.
• Confirm raw material specifications carry the purity and elemental impurity tests that support the finished product limits.
• Verify your stability programme supports the expiry date and every label claim, including any in-use period.
• Generate opened-container, in-use stability data for multiple-dose products where an in-use claim is made.
• Separate your GMP guide obligations from your Quality Guide obligations, and close gaps against both.
• Decide whether to submit a consultation comment before 20 September 2026, especially where a change would be costly for your product range.

Common mistakes

• Treating the GMP guide and the Quality Guide as the same document. They govern different things, and a strong site system does not fix a weak product specification.
• Relying on a generic purity statement instead of justified acceptance criteria for each contaminant category.
• Ignoring elemental impurities because a raw material certificate looked clean, without calculating the total daily exposure in the finished product.
• Printing an in-use period with no opened-container stability data to support it.
• Assuming the 2015 guide still defines the bar. The draft is the clearest signal of where Health Canada is heading, even before it is finalized.

How to comment before the deadline

The consultation opened on 20 July 2026 and closes to new input on 20 September 2026. The draft carries line numbers in the margin so that comments can point to a specific section. If a proposed expectation would be costly or impractical for your product range, a well-argued, evidence-based submission is the moment to say so, because the final version is expected later in 2026. Comments should be sent to the Natural and Non-prescription Health Products Directorate at the address on the consultation page.

Frequently asked questions

What is the difference between the NHP GMP guide and the NHP quality guide?

The GMP guide, GUI-0158, governs how you manufacture, package, label, import and test a natural health product at your site. The Quality Guide governs what your finished product must be shown to be, through its identity, quantity, potency, purity and stability. One is a site document, the other is a product document, and a licence holder needs both.

When does the new quality guide take effect?

The draft version 4.0 is in consultation until 20 September 2026. It is not yet in force. Health Canada intends to publish a final version later in 2026, followed by an appropriate transition period and implementation. Until the final version is published, the 2015 version 3.1 remains the operative guide, but the draft signals where expectations are heading.

Do I need to update my finished product specifications?

Very likely, yes, if your specifications were built against the 2015 guide. The draft is more explicit on purity, elemental impurities and in-use stability. Start with a gap review of your existing specifications so that any changes can be planned rather than rushed once the final guide is published.

What are the elemental impurity limits for natural health products in Canada?

The draft aligns limits with ICH guideline Q3D and its permitted daily exposures, reported in micrograms per day. The concentration limit for any element depends on the maximum daily intake of your product, and calculations should use the lowest body weight in the recommended population, such as infants where relevant. Elements including arsenic, cadmium, lead and mercury warrant particular attention.

What is an in-use period for a multiple-dose natural health product?

An in-use period is the length of time a product remains acceptable after it has first been opened. Under the draft, any in-use statement on the label must be truthful and supported by stability studies that mimic real consumer use, including opening, sampling and re-closing the container over the shelf life. Sterile and non-sterile multiple-dose products such as ophthalmic products need particular attention.

What is paragraph 44(2)(a) of the Natural Health Products Regulations?

Paragraph 44(2)(a) is the part of the Natural Health Products Regulations that requires detailed purity information to be included in a finished product specification. The draft Quality Guide leans on it directly, which is why purity controls are the area most licence holders should review first.

How MFLRC can help

MF License and Regulatory Consultants helps natural health product licence holders bring their quality files up to the standard the draft version 4.0 signals. Our quality assurance services cover finished product specification rebuilds, purity and elemental impurity testing strategy, and stability and in-use period planning, so that your product evidence reflects current expectations rather than a 2015 baseline.

Through our audit services we run a focused gap assessment of your specifications against the draft guide, and our regulatory affairs and licensing team can prepare a consultation submission on your behalf before 20 September, handle product licence amendments, and support QAP obligations across your product range.

Whether you are a domestic manufacturer, an importer, or a Canadian brand exporting to the United States under 21 CFR Part 111, our natural health products practice can turn the new Quality Guide from a compliance risk into a competitive advantage.

Conclusion

The draft Quality of Natural Health Products Guide is the most significant change to product quality expectations in more than a decade. It confirms that purity belongs in your finished product specifications under paragraph 44(2)(a), it aligns elemental impurities with ICH Q3D, and it puts the in-use period on the record for multiple-dose products. The final version is coming later in 2026, but the direction is already clear. Licence holders who read the draft now, run a gap review, and act before the deadline will be ready when the final guide lands. Those who wait for the final text will be doing the same work under time pressure.

Sources and references

• Health Canada, Draft for consultation: Quality of natural health products guide, Purity and Stability
• Natural Health Products Regulations (SOR/2003-196), including paragraph 44(2)(a)
• ICH guideline Q3D: Elemental impurities (ICH Quality Guidelines)
• Health Canada, Good manufacturing practices guide for natural health products (GUI-0158), version 4.0
• United States Pharmacopeia, General Chapter <2232> Elemental Contaminants in Dietary Supplements